Why Beam Therapeutics Inc.’s (BEAM) Stock Is Up 8.58%
As of Wednesday, August 19, Beam Therapeutics Inc.’s BEAM share price has surged by 8.58%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Commentary & Analysis
Is Beam Therapeutics Inc. (BEAM) Overvalued?
We dive into why Beam Therapeutics Inc. (BEAM) could be considered overvalued on 2026-08-04, based on AAII’s Value Score and Grade.Tudor Pop
Why Beam Therapeutics Inc.’s (BEAM) Stock Is Up 7.37%
As of Tuesday, August 04, Beam Therapeutics Inc.’s BEAM share price has surged by 7.37%, which has investors questioning if this is right time to sell.Rosalio Madrigal
What You Need to Know About Beam Therapeutics Inc.'s Q3 Earnings
Beam Therapeutics Inc.'s fiscal Q3 earnings report was released on Tuesday, August 04. Let's dive in to see if (BEAM) missed or beat analyst's expectations.Tudor Pop
Why Beam Therapeutics Inc.’s (BEAM) Stock Is Down 6.13%
As of Thursday, July 16, Beam Therapeutics Inc.’s BEAM share price has dipped by 6.13%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | BEAM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,836.9 | $286.3 | 58% |
|
| Shares Out (Mil) | 104.3 | 54.2 | 63% |
|
| Institutional Ownership | 98.6% | 92.8% | 80% |
|
| Float (Mil) | 88.2 | 39.7 | 58% |
|
| Beta | 2.21 | 0.94 | 95% |
|
| Avg Daily Volume (000s) | 1,683 | 534 | 79% |
|
| Price Change (52-week) |
73.6% | 58.7% | 86% |
|
| Growth | BEAM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 16.3% | (10.1%) | 66% |
|
| EPS (5yr) | 28.0% | 16.0% | 79 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (46.4%) | (15.6%) | 8% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 13 | 14 | 12 | |
| Current EPS | ($1.170) | ($4.454) | ($4.741) | |
| Month Ago EPS | ($1.174) | ($4.435) | ($4.732) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($1.181) | ($4.469) | ($4.744) | |
| Year/Year Chg | (0.5%) | 450.6% | 452.5% | |
| Financials | BEAM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $156 | $37 | 30% |
|
| Net Income (TTM) (Mil) | ($87) | ($43) | 12% |
|
| EPS (TTM) | ($0.838) | ($1.400) | 23% |
|
| Operating Cash Flow (TTM) (Mil) | ($359) | ($31) | 2% |
|
| Net Cash Flow (TTM) (Mil) | ($62) | $2 | 18% |
|
| Long-Term Debt (Q1) (Mil) | $232 | $4 | 51% |
|
| Enterprise Value (Q1) (Mil) | $1,799 | $160 | 48% |
|
| Valuation | BEAM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.66 | 2.77 | 60% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | BEAM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (161.9%) | 64.2% | 1% |
|
| Net Margin | (55.4%) | (75.9%) | 11% |
|
| ROA | (6.2%) | (47.3%) | 28% |
|
| ROE | (8.2%) | (55.0%) | 29% |
|
| Liabilities to Assets | 23.0% | 29.6% | 15% |
|
| F-Score | 4 | 2 | 34% |
|
Beam Therapeutics Inc. did not pass any screens on 8/20/2026.
